Exide technologies – Technology news and features for New Scientist editors.

Read moreExide Technologies has developed a new treatment for HIV that works like an antivirus.

The new drug can prevent HIV infections from going unnoticed by the body’s immune system and preventing the virus from getting re-infected, allowing people to remain free of the virus for longer.

The company said it is now testing a version of the drug in a trial of about 500 people who have tested positive for HIV.

The drug is an antibody-based treatment called exide (exide is short for exadex-5), which can stop HIV from spreading through blood or other body fluids.

It has not been tested in people who already have the virus, so it is unclear how effective it will be in that group.

Exide Technology chief executive Ian King said the drug’s ability to prevent HIV from getting into the body could have significant benefits for people living with HIV, such as those who are HIV-positive.

“It is very exciting that the first HIV-preventive treatment to target HIV has been developed,” he said.

“Exide is an anti-viral medication that blocks viral replication in the body.

This is a significant step forward in the development of HIV prevention treatments.”

The drug works by targeting the proteins in the virus that make it easier for it to re-spread.

Exide’s main active ingredient is a peptide called exadeX-5 that is extracted from the virus’ RNA, a process known as RNAi.

“We are currently testing exideX-6 as a second active ingredient, to make the peptide available to the immune system,” King said.

Exiding HIV is an important development in the fight against HIV because the virus is currently spread in close contact with the body through sexual activity.

ExIDE said it was working with partners to develop exide as a vaccine.

It also is working on an experimental therapy for HIV, which is already available in Australia.

Exides drug uses antibodies that are similar to those produced by the immune systems of people with HIV.

These antibodies bind to the viral RNA and attack it.

Exides antibodies have shown promise in testing and treating HIV.

ExidueX-4 is a different type of antibody drug, which can be used in combination with other drugs to block viral replication.

Exidue is a stronger antibody than Exide but is not yet ready for testing.

“The main difference between Exide and ExideX is that Exide has the ability to kill HIV, but Exide does not,” King added.

Exidaption, a drug made by Exide, is an active ingredient in Exide.

It is currently in clinical trials and has been shown to be safe and effective in HIV patients.

Exidaption is being tested in the UK, where it is being used to treat people with a rare form of the disease.

Exidy, a protein that exudes from the immune cells of people infected with HIV or AIDS, is a new HIV treatment.

It works by attacking the virus and preventing it from replicating in the immune cell.

It could be the first anti-reactive protein drug to be approved in Australia for HIV treatment in people with the virus.

The Exidy drug, made by Oxford University, has shown promising results in trials in people.

Exidy is currently undergoing clinical trials in Australia and the US.

Exision said it would continue to work with researchers in Australia to find a suitable partner to develop Exide drugs in Australia, and the company said Australia was the next stop in a new development pathway.